<DOC>
	<DOCNO>NCT01531309</DOCNO>
	<brief_summary>Agomelatine ( AGO178 ) develop treatment depression . A new formulation test present study : tablet place dissolve tongue ( sublingual tablet ) . The goal trial study pharmacokinetics agomelatine give sublingual tablet patient liver impairment compare result healthy volunteer receive treatment .</brief_summary>
	<brief_title>Pharmacokinetics Agomelatine Patients With Liver Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>S 20098</mesh_term>
	<criteria>Patients liver disease confirm within 3 month screen If liver impairment cause alcohol use , patient must abstain alcohol use within 3 month study start Patients must satisfy criterion Child Pugh Class A B Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer Pregnant nursing ( lactate ) woman Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective contraception study Donation loss 400 mL blood within eight ( 8 ) week prior initial dose Significant illness within two week prior dose Patients ChildPugh alteration due nonliver disease ( e.g . cancer treatment related weight loss ) . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Liver impairment</keyword>
	<keyword>Major Depression Disorder</keyword>
	<keyword>Sublingual tablet</keyword>
</DOC>